Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amylyx’ Second Chance Advisory Committee: Two Quasi-Precedents

Jul 08 2022

• By Michael McCaughan

WHITE OAK, MD - JULY 20: A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland. (Photo by Sarah Silbiger/Getty Images) — • Source: Sarah Silbiger/Getty Images (Sarah Silbiger/Getty Images)

Related Content

Will Amylyx’s ALS Drug Benefit From US FDA’s Aduhelm Experience?

Jul 05 2022

Aducanumab Review: Looking For Precedents – Long Ago And Far Afield

Dec 01 2020

WARNER LAMBERT's COGNEX: FDA ADVISORY COMMITTEE UNABLE TO RECOMMEND APPROVAL

Mar 18 1991

INTERNEURON DEXFENFLURAMINE COGNITIVE STUDY FINDS NO EVIDENCE OF NEUROTOXICITY; ADVISORY COMMITTEE RECOMMENDS OBESITY THERAPY BY SLIM MARGIN

Nov 20 1995

Interneuron dexfenfluramine advisory committee review to resume Nov. 16.

Oct 09 1995

Related Companies

Amylyx Pharmaceuticals, Inc.

Additional Topics

United States Advisory Committees Drug Review Regulation Neurology BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window